The Egyptian Journal of Haematology

ORIGINAL ARTICLE
Year
: 2019  |  Volume : 44  |  Issue : 2  |  Page : 77--81

Vitamin D supplementation does not affect survival in patients with Hodgkin’s lymphoma


Ahmed M.L Bedewy1, Noha S Kandil2,  
1 Department of Hematology, Medical Research Institute, Alexandria University, Alexandria, Egypt
2 Department of Chemical Pathology, Medical Research Institute, Alexandria University, Alexandria, Egypt

Correspondence Address:
Ahmed M.L Bedewy
Abraj Al-Shaker, Smouha, Alexandria, 21615
Egypt

Abstract

Background Hodgkin’s lymphoma (HL) is a B-cell lymphoproliferative tumor that has an excellent prognosis in most patients using chemotherapeutic protocols, with or without radiation. Some populations including aged people and adolescents and young adults did not gain similar benefits from treatment advances when compared with pediatric and other adult patients. Vitamin D deficiency was suggested as a risk factor for many malignant tumors, and its supplementation may have a role in management of some cancers. Aim This study aimed to evaluate vitamin D levels in patients with HL at presentation and after 12 weeks of supplementation in relation to treatment outcome. Patients and methods A total of 24 treatment-naive patients with pathologically confirmed HL were consecutively recruited. Vitamin D levels were assessed at presentation and after 12 weeks of vitamin D supplementation using automated electrochemiluminescence binding assay. All patients received ABVD protocol as a first-line therapy. The outcome of patients after the six cycles was classified as complete response, partial response, stable disease, or relapsed/progressive disease. Results Female patients and those with B symptoms had significantly lower vitamin D levels (P=0.032 and 0.045, respectively). Patients who failed to respond to ABVD had significantly lower vitamin D levels compared with that of responders (P=0.022). Vitamin D levels did not affect progression-free survival (log-rank test P=0.69). Conclusion Lower vitamin D level was associated with nonresponsiveness to ABVD regimen. Vitamin D supplementation in patients with HL did not alter the progression-free survival of the studied patients. However, these findings await more validation through recruiting larger cohorts of patients for longer follow-up periods.



How to cite this article:
Bedewy AM, Kandil NS. Vitamin D supplementation does not affect survival in patients with Hodgkin’s lymphoma.Egypt J Haematol 2019;44:77-81


How to cite this URL:
Bedewy AM, Kandil NS. Vitamin D supplementation does not affect survival in patients with Hodgkin’s lymphoma. Egypt J Haematol [serial online] 2019 [cited 2020 Mar 28 ];44:77-81
Available from: http://www.ehj.eg.net/text.asp?2019/44/2/77/271076


Full Text



 Introduction



Hodgkin lymphoma (HL) is a B-cell lymphoproliferative tumor that has an excellent prognosis in most patients using chemotherapeutic protocols, with or without radiation [1]. However, high-dose therapy combined with autologous hematopoietic cell transplant may be needed in patients with refractory/relapsed disease [2]. In addition, some populations including aged people [3] and adolescents and young adults [4] did not gain similar benefits from treatment advances when compared with pediatric and other adult patients.

Inspired by the continuous need for innovative and alternative treatment approaches [5], treatment of HL remains under continuous evolvement which includes better identification of significant risk factors, more sensitive diagnostic utilities, and more effective therapeutic approaches [6].

Vitamin D is a steroid-like hormone that exerts its pleotropic actions via binding to vitamin D receptor. Vitamin D deficiency was suggested as a risk factors for many malignant tumors, including bone [7], gynecological [8], cutaneous [9] and hematological malignancies [10],[11]. Evidence derived from clinical [12],[13] and experimental [14] studies suggested vitamin D supplementation may have a role in management of some cancers.

In hematological malignancies, it is thought that the role of vitamin D in regulation of immune cell functions and maturation and proliferation of hematopoietic cells makes it a promising candidate for treatment of these malignancies [15],[16].

 Patients and methods



This is a prospective study conducted at the Medical Research Institute, Alexandria University. The study protocol was conducted in accordance with the Helsinki Declaration for medical research involving human participants. The study prospectively recruited a cohort of 24 consecutive treatment-naive patients with pathologically confirmed HL. Patients were excluded if they were on vitamin D supplementation or if they had surgical or medical condition that can interfere with adequate intestinal absorption.

Before treatment, patients were subjected to standard clinical, laboratory, and radiological assessment. Patients were classified according to WHO classification of hematopoietic tumors [17],[18]. Tumor was staged according to Cotswold Modification of Ann Arbor Staging System [19] and performance status was assessed according to Eastern Cooperative Oncology Group Performance Scale [20]. The international prognostic index was used to estimate disease prognosis [21].

Vitamin D levels were assessed at presentation and after 12 weeks of vitamin D supplementation. The serum level of vitamin D was assayed using automated electrochemiluminescence binding assay for the in-vitro quantitative determination of total 25-hydroxy vitamin D (Cobas E411 analyzer; Roche, Berlin, Germany). Obtained levels were classified as normal (≥30 ng/ml), insufficient (20–29.9 ng/ml), or deficient (<20 ng/ml) [22]. For vitamin D supplementation, we used oral liquid vitamin D3 preparations according to the instructions described by Khan and Fabian [23].

All patients received ABVD protocol as a first-line therapy (doxorubicin, bleomycin, vinblastine, and dacarbazine) [24]. The response of patients after the six cycles was classified as complete response, partial response, stable disease, or relapsed/progressive disease according to the criteria described by Cheson et al. [25]. Patients who responded to ABVD were followed up for progression-free survival (PFS) (median 20 months, range: 11–35 months).

Statistical analysis was achieved using SPSS 25 (IBM, New York, USA). Numerical variables were expressed as mean±SD whereas categorical data were represented as number and percent. Statistical comparisons were achieved using t-test, paired t-test, or one-way analysis of variance for numerical data and χ2-test for categorical data. The Kaplan–Meier method was used to estimate the probabilities of PFS and the log-rank test was used for univariate comparisons between groups.

 Results



Vitamin D level at presentation ranged from 4.8 to 21.4 IU/ml, with a mean of 11.54±4.23 IU/ml. The relation between baseline vitamin D levels and the clinicolaboratory data of the studied patients is shown in [Table 1]. Female patients and those with B symptoms had significantly lower vitamin D levels (P=0.032 and 0.045, respectively). Moreover, patients with inferior Eastern Cooperative Oncology Group performance status had significantly lower vitamin D levels (P=0.045).{Table 1}

Vitamin D supplementation resulted in significant improvement of vitamin D levels from 11.5±4.2 to 33.3±8.9 IU/ml (P<0.001) and normalizing the vitamin levels in 11 (45.8%) patients ([Table 2]). Patients who failed to respond to ABVD had significantly lower vitamin D levels compared with that of responders (P=0.022). Vitamin D status after 12 weeks supplementation was not associated with significant difference in PFS (log-rank test P=0.69; [Table 3] and [Figure 1]).{Table 2}{Table 3}{Figure 1}

 Discussion



The relation between vitamin D levels and the biology of various types of cancers remains a matter of continuous debate with many inconsistencies and controversies. The present study sought to contribute to this debate by studying baseline vitamin D levels in patients with HL, a set of patients who were rarely investigated for this association. Moreover, the study used vitamin D supplementation to discover the effect of correction of vitamin D status on treatment outcome.

In this study, all patients with HL had insufficient (4.2%) to deficient (95.8%) vitamin D levels at baseline. This prevalence is fairly higher than prevalence reported by other studies on healthy Egyptian populations [26],[27],[28],[29].

Although we should be cautious when interpreting this surprising finding, it raises attention about the association between developing HL and vitamin D deficiency. In this context, the secondary analysis conducted by Ammann et al. [30] on data from the Women’s Health Initiative calcium/vitamin D trial found that vitamin D supplementation was associated with protective effects against hematological malignancies. In contrast, the meta-analysis conducted by Lu et al. [31] concluded that high vitamin D levels does not provide protective effects against the development of non-HL. Moreover, a large study with a long-term follow-up period found no significant relation between high-dose vitamin D supplementation and reduction of cancer incidence [32].

The significantly lower baseline vitamin D levels in female patients is our cohort is a common finding is Egyptian women. It is mainly related to low outdoor activity together with the traditional clothing habits [29]. Patients with B symptoms had significantly lower vitamin D levels. This finding was also reported by the recent study of Hohaus et al. [13] on patients with aggressive lymphoma and may give a useful clue to understand the etiology of these manifestations in hematological malignancies patients.

Supplementing our patients with vitamin D resulted in normalizing the hormone levels in 11 (45.8%) patients and converting other patients from deficiency to the insufficiency state. These results are comparable to the vitamin D supplementation protocol adopted by Hohaus et al. [13] which produced normal vitamin D levels in 56.0% of patients.

In this study, vitamin D level was lower in nonresponders compared with ABVD-responsive patients. However, vitamin D status did not affect their PFS. These data are supported by the conclusions of Székely et al. [33] who studied the effect of season of diagnosis on the patients with diffuse large B-cell lymphoma and HL. They noted that although diffuse large B-cell lymphoma cases diagnosed during summer had better overall survival, this did not apply to patients with HL. Moreover, the study of Shanafelt et al. [34] failed to document as association between overall survival and vitamin D levels.

In contrast, Drake et al. [35] found that patients with NHL with lower vitamin D levels had inferior event-free survival and overall survival. Similar conclusions were reported by the studies of Kelly et al. [36] and Tracy et al. [11] on patients with follicular lymphoma. Moreover, the recent study of Djurasinović et al. [37] on patients with lymphoid malignancies including HL found significantly lower progression rate and better event-free survival in patients with higher vitamin D levels. However, results of various tumor types were not revealed in the study.

Conclusively, lower vitamin D level was associated with nonresponsiveness to ABVD regimen. Vitamin D supplementation in patients with HL did not alter the PFS of the studied patients. However, these findings await more validation through recruiting larger cohorts of patients for longer follow-up periods.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.

References

1Von Keudell G, Younes A. Novel therapeutic agents for relapsed classical Hodgkin lymphoma. Br J Haematol 2019; 184:105–112.
2Shah GL, Moskowitz CH. Transplant strategies in relapsed/refractory Hodgkin lymphoma. Blood 2018; 131:1689–1697.
3Lim SH, Johnson PWM. Optimizing therapy in advanced-stage Hodgkin lymphoma. Blood 2018; 131:1679–1688.
4Crombie JL, LaCasce AS. Current considerations in AYA Hodgkin lymphoma. Br J Haematol 2019; 184:72–81.
5Mottok A, Steidl C. Biology of classical Hodgkin lymphoma: implications for prognosis and novel therapies. Blood 2018; 131:1654–1665.
6Spinner MA, Advani RH, Connors JM, Azzi J, Diefenbach C. New treatment algorithms in Hodgkin lymphoma: too much or too little? Am Soc Clin Oncol Educ Book 2018; 38:626–636.
7Horas K, Maier G, Jakob F, Maus U, Kurth A, Jakuscheit A et al. High prevalence of vitamin D deficiency in patients with bone tumors. Cancer Invest 2017; 35:562–568.
8Yan L, Gu Y, Luan T, Miao M, Jiang L, Liu Y et al. Associations between serum vitamin D and the risk of female reproductive tumors: a meta-analysis with trial sequential analysis. Medicine (Baltimore) 2018; 97:e0360.
9Lim A, Shayan R, Varigos G. High serum vitamin D level correlates with better prognostic indicators in primary melanoma: a pilot study. Australas J Dermatol 2018; 59:182–187.
10Seyedalipour F, Mansouri A, Vaezi M, Gholami K, Heidari K, Hadjibabaie M et al. High prevalence of vitamin D deficiency in newly diagnosed acute myeloid leukemia patients and its adverse outcome. Int J Hematol Oncol Stem Cell Res 2017; 11:209–216.
11Tracy SI, Maurer MJ, Witzig TE, Drake MT, Ansell SM, Nowakowski GS et al. Vitamin D insufficiency is associated with an increased risk of early clinical failure in follicular lymphoma. Blood Cancer J 2017; 7:e595.
12De Smedt J, van Kelst S, Boecxstaens V, Stas M, Bogaerts K, Vanderschueren D et al. Vitamin D supplementation in cutaneous malignant melanoma outcome (ViDMe): a randomized controlled trial. BMC Cancer 2017; 17:562.
13Hohaus S, Tisi MC, Bellesi S, Maiolo E, Alma E, Tartaglia G et al. Vitamin D deficiency and supplementation in patients with aggressive B-cell lymphomas treated with immunochemotherapy. Cancer Med 2018; 7:270–281.
14Mukai Y, Yamada D, Eguchi H, Iwagami Y, Asaoka T, Noda T et al. Vitamin D supplementation is a promising therapy for pancreatic ductal adenocarcinoma in conjunction with current chemoradiation therapy. Ann Surg Oncol 2018; 25:1868–1879.
15Medrano M, Carrillo-Cruz E, Montero I, Perez-Simon JA. Vitamin D: effect on haematopoiesis and immune system and clinical applications. Int J Mol Sci 2018; 19:2663.
16Liu W, Zhang L, Xu HJ, Li Y, Hu CM, Yang JY et al. The anti-inflammatory effects of vitamin D in tumorigenesis. Int J Mol Sci. 2018; 19:E2736.
17Jaffe ES, Harris NL, Stein H, Vardiman JW. Pathology and genetics of tumours of haematopoietic and lymphoid tissues. Third edition. Lyon: IARC Press. 2001. p. 351.
18Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri EA, Stein H et al. WHO classification of tumours of haematopoietic and lymphoid tissues. Fourth edition. Lyon, France: International Agency for Research on Cancer. 2008. p. 439.
19Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol 2014; 32:3059–3068.
20Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5:649–655.
21Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin’s disease. International Prognostic Factors Project on Advanced Hodgkin’s Disease. N Engl J Med 1998; 339:1506–1514.
22Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, Heaney RP et al. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2011; 96:1911–1930.
23Khan QJ, Fabian CJ. How I treat vitamin d deficiency. J Oncol Pract 2010; 6:97–101.
24Eich HT, Diehl V, Gorgen H, Pabst T, Markova J, Debus J et al. Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin’s lymphoma: final analysis of the German Hodgkin Study Group HD11 trial. J Clin Oncol 2010; 28:4199–4206.
25Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007; 25:579–586.
26Amr N, Hamid A, Sheta M, Elsedfy H. Vitamin D status in healthy Egyptian adolescent girls. Georgian Med News 2012; 210:65–71.
27Ragab WS, Saleh WF, Tawfik LT. Vitamin D deficiency in postmenopausal Egyptian women. Int J Gynaecol Obstet 2013; 123:75–76.
28Aly WW, Hussein MA, Moahamed Ebeid S, Mortagy AK. Prevalence of vitamin D insufficiency among community dwelling elderly in Dakahlia as a representative of rural areas in Egypt. Aging Clin Exp Res 2014; 26:47–51.
29Botros RM, Sabry IM, Abdelbaky RS, Eid YM, Nasr MS, Hendawy LM. Vitamin D deficiency among healthy Egyptian females. Endocrinol Nutr 2015; 62:314–321.
30Ammann EM, Drake MT, Haraldsson B, Wallace RB, Johnson KC, Desai P et al. Incidence of hematologic malignancy and cause-specific mortality in the Women’s Health Initiative randomized controlled trial of calcium and vitamin D supplementation. Cancer 2017; 123:4168–4177.
31Lu D, Chen J, Jin J. Vitamin D status and risk of non-Hodgkin lymphoma: a meta-analysis. Cancer Causes Control 2014; 25:1553–1563.
32Scragg R, Khaw KT, Toop L, Sluyter J, Lawes CMM, Waayer D et al. Monthly high-dose vitamin D supplementation and cancer risk: a post hoc analysis of the vitamin D assessment randomized clinical trial. JAMA Oncol 2018; 4:e182178.
33Szekely E, Linden O, Peterson S, Jerkeman M. Season of diagnosis is associated with overall survival in patients with diffuse large B-cell lymphoma but not with Hodgkin’s lymphoma − a population-based Swedish Lymphoma Register study. Eur J Haematol 2016; 97:393–398.
34Shanafelt TD, Drake MT, Maurer MJ, Allmer C, Rabe KG, Slager SL et al. Vitamin D insufficiency and prognosis in chronic lymphocytic leukemia. Blood 2011; 117:1492–1498.
35Drake MT, Maurer MJ, Link BK, Habermann TM, Ansell SM, Micallef IN et al. Vitamin D insufficiency and prognosis in non-Hodgkin’s lymphoma. J Clin Oncol 2010; 28:4191–4198.
36Kelly JL, Salles G, Goldman B, Fisher RI, Brice P, Press O et al. Low serum vitamin D levels are associated with inferior survival in follicular lymphoma: a prospective evaluation in SWOG and LYSA studies. J Clin Oncol 2015; 33:1482–1490.
37Djurasinovic VT, Mihaljevic BS, Sipetic Grujicic SB, Ignjatovic SD, Trajkovic G, Todorovic-Balint MR et al. 25(OH) vitamin D deficiency in lymphoid malignancies, its prevalence and significance. Are we fully aware of it? Support Care Cancer 2018; 26:2825–2832.